Servier has announced that it will stop developing sevasemten for Becker and Duchenne muscular dystrophy following results from its GRAND CANYON clinical trial.
Servier to stop trials of sevasemten for Becker and Duchenne muscular dystrophy
Following the recent announcement that the GRAND CANYON clinical trial did not meet its main goals, pharmaceutical company Servier has now confirmed that it will stop developing sevasemten for both Becker muscular dystrophy (BMD) and Duchenne muscular dystrophy (DMD).
The decision follows a review of results from the phase 3 GRAND CANYON study in BMD, as well as phase 2 studies in DMD. Unfortunately, the studies did not provide enough evidence that sevasemten improved muscle function compared with placebo.
What do the results tell us about safety?
While this news will be disappointing for many people and families in the BMD and DMD communities, Servier has reported that no new safety concerns were identified during the studies. The safety profile of sevasemten remained similar to that seen in previous research.
What next?
Although the development programme is coming to an end, researchers will continue to analyse the data collected from participants. The information gained from these studies will help researchers better understand BMD and DMD and could help inform future research and drug development.
We recognise the contribution of everyone who took part in these studies. Clinical research relies on the commitment of participants and their families, and every study, regardless of the outcome, helps to build knowledge that can move the field forward.
Servier has said it plans to hold webinars for the community and will share more information as it becomes available.
If you have questions about what this announcement means for you or your family, please speak to your clinical team or get in touch with our Research team.